M&A Update – June 12

– KDNY to be acquired by Novartis for $40.00 cash per share + CVR of up to $4.00, 66.7% premium, $3.5 billion
– CS / UBS deal closed
– CTIC / Swedish Orphan Biovitrum AB (Sobi) cleared HSR
– TRTN / BIPC cleared HSR, closing Q4 2023
– RADI / EQT and Public Sector Pension Investment Board (PSP) cleared China SAMR
– DCP / PSX delisting notice, closing June 15
– BGRY filed PRER14a for SoftBank buyout, no meeting date set